Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

If the dose is missed for more than 1 week then the patients should skip the missed dose and take the next dose at the specified time schedule. Dupilumab is prescribed for the treatment of ...

M ONDAY, Aug. 12, 2024 (HealthDay News) -- For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients ...

Study participants were randomly assigned 1:1 to receive dupilumab or placebo subcutaneously every 2 weeks for 52 weeks, in addition to triple therapy. The primary endpoint in both trials was the ...

In the current trial, we evaluated dupilumab in children 1 to 11 years of age with active eosinophilic esophagitis that was refractory to proton-pump inhibitor therapy. We conducted the trial in ...

1 The results showed that temtokibart 450 mg once every 2 weeks dosing (Q2W, n=8) significantly improved skin hydration faster and to a greater extent than dupilumab 300 mg Q2W (n=4). 1 ...

Treatment-emergent adverse events (TEAEs) were the same for both groups (53%), with nasopharyngitis being the most common (8.1% with dupilumab and 5.2% with placebo). Injection site erythema was ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO ...

The late-breaking data to be presented at ACG feature results from children enrolled in the extended active treatment period (Part B) of a Phase 3 trial, following 16 weeks of Dupixent treatment ...